Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
22 Aug 2022
22 Aug 2022
Historique:
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
South Africa was among the first countries to detect the SARS-CoV-2 Omicron variant. Propelled by increased transmissibility and immune escape properties, Omicron displaced other globally circulating variants within 3 months of its emergence. Due to limited testing, Omicron's attenuated clinical severity, and an increased risk of reinfection, the size of the Omicron BA.1 and BA.2 subvariants (BA.1/2) wave remains poorly understood in South Africa and in many other countries. Using South African data from urban and rural cohorts closely monitored since the beginning of the pandemic, we analyzed sequential serum samples collected before, during, and after the Omicron BA.1/2 wave to infer infection rates and monitor changes in the immune histories of participants over time. Omicron BA.1/2 infection attack rates reached 65% (95% CI, 60% - 69%) in the rural cohort and 58% (95% CI, 61% - 74%) in the urban cohort, with repeat infections and vaccine breakthroughs accounting for >60% of all infections at both sites. Combined with previously collected data on pre-Omicron variant infections within the same cohorts, we identified 14 distinct categories of SARS-CoV-2 antigen exposure histories in the aftermath of the Omicron BA.1/2 wave, indicating a particularly fragmented immunologic landscape. Few individuals (<6%) remained naïve to SARS-CoV-2 and no exposure history category represented over 25% of the population at either cohort site. Further, cohort participants were more than twice as likely to get infected during the Omicron BA.1/2 wave, compared to the Delta wave. Prior infection with the ancestral strain (with D614G mutation), Beta, and Delta variants provided 13% (95% CI, -21% - 37%), 34% (95% CI, 17% - 48%), and 51% (95% CI, 39% - 60%) protection against Omicron BA.1/2 infection, respectively. Hybrid immunity (prior infection and vaccination) and repeated prior infections (without vaccination) reduced the risks of Omicron BA.1/2 infection by 60% (95% CI, 42% - 72%) and 85% (95% CI, 76% - 92%) respectively. Reinfections and vaccine breakthroughs had 41% (95% CI, 26% - 53%) lower risk of onward transmission than primary infections. Our study sheds light on a rapidly shifting landscape of population immunity, along with the changing characteristics of SARS-CoV-2, and how these factors interact to shape the success of emerging variants. Our findings are especially relevant to populations similar to South Africa with low SARS-CoV-2 vaccine coverage and a dominant contribution of immunity from prior infection. Looking forward, the study provides context for anticipating the long-term circulation of SARS-CoV-2 in populations no longer naïve to the virus.
Identifiants
pubmed: 36032973
doi: 10.1101/2022.08.19.22278993
pmc: PMC9413704
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NCIRD CDC HHS
ID : U01 IP001048
Pays : United States
Organisme : ACL HHS
ID : U01IP001048
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Am J Epidemiol. 1982 May;115(5):736-51
pubmed: 7081204
Emerg Infect Dis. 2018 Oct;24(10):1882-1888
pubmed: 30226161
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Sci Immunol. 2022 Sep 16;7(75):eabq2427
pubmed: 35653438
Cold Spring Harb Perspect Med. 2022 May 27;12(5):
pubmed: 35444005
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Emerg Infect Dis. 2022 Mar;28(3):672-683
pubmed: 35202525
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
Cell Host Microbe. 2022 Jun 8;30(6):880-886.e4
pubmed: 35436444
Sci Immunol. 2022 Sep 23;7(75):eabq4450
pubmed: 35737747
Science. 2022 Jun 17;376(6599):1327-1332
pubmed: 35608456
Lancet. 2022 Apr 16;399(10334):1513-1536
pubmed: 35279232
Science. 2022 Mar 11;375(6585):1151-1154
pubmed: 35084937
Clin Chem Lab Med. 2020 Dec 18;59(5):e179-e183
pubmed: 33554588
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Science. 2022 Nov 11;378(6620):619-627
pubmed: 36264829
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Virus Evol. 2022 May 11;8(1):veac021
pubmed: 35573973
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Nat Rev Immunol. 2022 Feb;22(2):69-71
pubmed: 35046570
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Emerg Infect Dis. 2021 Dec;27(12):3020-3029
pubmed: 34477548
Sci Transl Med. 2022 Aug 24;14(659):eabo7081
pubmed: 35638937
Lancet. 2022 Jan 29;399(10323):437-446
pubmed: 35065011
Nat Rev Immunol. 2022 May;22(5):267-269
pubmed: 35414124
Lancet Infect Dis. 2022 Jun;22(6):821-834
pubmed: 35298900
Nat Med. 2022 Sep;28(9):1933-1943
pubmed: 35675841
Science. 2021 Dec 3;374(6572):1179
pubmed: 34855502
Microbiol Spectr. 2022 Aug 31;10(4):e0098622
pubmed: 35867423
PLoS Pathog. 2012;8(12):e1003061
pubmed: 23271967
Lancet Infect Dis. 2022 Jul;22(7):943-945
pubmed: 35691303
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
BMC Infect Dis. 2022 Feb 5;22(1):127
pubmed: 35123418
Science. 2022 Jul 15;377(6603):eabq1841
pubmed: 35699621
N Engl J Med. 2022 May 5;386(18):1764-1766
pubmed: 35320661